Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEA (Levagen+) for Migraine
NCT05046522Phase 3Completed
- Sponsor
- RDC Clinical
- Start
- Sep 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of palmitoylethanolamide in migraine, sponsored by RDC Clinical. Started Sep 2021; status: completed.
02
Drugs
palmitoylethanolamide
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05046522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05046522.